MedTrace Logo

Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma

NCT02633137 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2024-08-30

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to find out what effects, good and/or bad, the treatment including 1) Lenalidomide-RCHOP, 2) R-HIDAC, and 3) Lenalidomide-Rituximab maintenance has on the participant and their lymphoma.

Conditions

Interventions

DRUG

Lenalidomide

DRUG

R-CHOP

* Rituximab 375 mg/m\^2 IVPB with premedications Day 1 * Cyclophosphamide 750 mg/m\^2 IVPB Day 1 * Doxorubicin 50 mg/m\^2 IVP Day 1 * Vincristine 1.4 mg/m\^2 IVP (capped at 2 mg) Day 1 * Prednisone 100 mg PO Daily on Days 1-5 or 2-6

DRUG

high-dose cytarabine (HIDAC)

Sponsors & Collaborators

Principal Investigators

  • Anita Kumar, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-14
Primary Completion
2023-11-07
Completion
2023-11-07

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02633137 on ClinicalTrials.gov